Skip to main content
SpringerLink
Log in

Biologic and Emerging Therapies for Allergic Disease

  • Living reference work entry
  • First Online:
Allergy and Asthma

  • 253 Accesses

Abstract

Biologic therapies can be used to treat allergic diseases, which is when the body overreacts or inappropriately responds to normally harmless substances. Several biologic therapies have been successfully developed to treat severe and recalcitrant allergic diseases. Currently approved biologics for the treatment of allergic diseases are omalizumab, benralizumab, mepolizumab, reslizumab, and dupilumab. The majority of these approved biologics are for asthma, but treatment for chronic idiopathic urticaria and atopic dermatitis is also available. Additional research is ongoing for the use of other biologic therapies in a variety of allergic disorders. Approved and investigational biologic therapies for allergic diseases are reviewed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Abbreviations

CIU:

Chronic idiopathic urticaria

EASI:

Eczema Area and Severity Index

EASI-50:

Proportion of patients who reach 50% improvement as based on the EASI score

EASI-75:

Proportion of patients who reach 75% improvement as based on the EASI score

FcεRI:

High-affinity IgE receptor

FDA:

Food and Drug Administration

FeNO:

Fractional exhaled nitric oxide

FEV1:

Forced expiratory volume in 1 second

ICS:

Inhaled corticosteroid

IGA:

Investigator’s Global Assessment

IgE:

Immunoglobulin E

IL:

Interleukin

IL-4R:

Interleukin-4 receptor

ILC-2:

Type 2 innate lymphoid cells

LABA:

Long-acting beta-adrenoceptor agonist

LTRA:

Leukotriene receptor antagonist

PGD2 receptor:

Prostaglandin D2 receptor

SCORAD:

Scoring Atopic Dermatitis

TH-2:

T-helper lymphocyte type 2

TSLP:

Thymic stromal lymphopoietin

References

  • (2015) FDA approves Nucala to treat severe asthma. In: U.S. Food Drug Adm. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471031.htm. Accessed 1 Feb 2018.

  • (2016) Full Prescribing Information, CINQAIR. In: CINQAIR Website, Teva Respir. LLC. http://ginasthma.org/wp-content/uploads/2016/04/GINA-2016-main-report_tracked.pdf. Accessed 15 Nov 2017.

  • (2016) Full Prescribing Information, ZINBRYTA. In: Zinbryta Website, Biog.

    Google Scholar 

  • (2017) Full Prescribing Information, DUPIXENT. In: Dupixent Website, Regen. Pharm. Inc. https://www.regeneron.com/sites/default/files/Dupixent_FPI.pdf. Accessed 10 Dec 2017.

  • (2017) Full Prescribing Information, FASENRA. In: Fasenra Website, AstraZeneca.

    Google Scholar 

  • (2017) Full Prescribing Information, NUCALA. In: Nucala Website, GlaxoSmithKline LLC.

    Google Scholar 

  • (2017) Full Prescribing Information, XOLAIR. In: Xolair Website, Genentech USA, Inc.

    Google Scholar 

  • Ädelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Della Cioppa G, Sandström T. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253–9.

    Article  Google Scholar 

  • Adkinson NF Jr, Bochner BS, Burks AW, Busse WW, Holgate ST, Lemanske RR, O’Hehir RE. Middleton’s allergy principles and practice. 8th ed. Philadelphia: Elsevier/Saunders; 2014.

    Google Scholar 

  • Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5:1362–70.e2.

    Article  Google Scholar 

  • Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E, Spergel AR, Desai M, Galli SJ, Nadeau KC, Chinthrajah RS. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3:85–94.

    Article  Google Scholar 

  • Assa’ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, Perschy TL, Jurgensen CH, Ortega HG, Aceves SS. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141:1593–604.

    Article  Google Scholar 

  • AstraZeneca. AstraZeneca provides update on tralokinumab Phase III programme in severe, uncontrolled asthma. In: AstraZeneca.com. 2017. https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-provides-update-on-tralokinumab-phase-iii-programme-in-severe-uncontrolled-asthma-01112017.html.

  • Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy Eur J Allergy Clin Immunol. 2004;59:701–8.

    Article  CAS  Google Scholar 

  • Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, Pirozzi G, Graham NM, Swanson B, Hamilton JD, Radin A, Gandhi NA, Stahl N, Yancopoulos GD, Sutherland ER. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. JAMA. 2016;315:469.

    Article  CAS  Google Scholar 

  • Barnes PJ. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol. 2015;136:531–45.

    Article  Google Scholar 

  • Barranco P, Phillips-Angles E, Dominguez-Ortega J, Quirce S. Dupilumab in the management of moderate-to-severe asthma: the data so far. Ther Clin Risk Manag. 2017;13:1139–49.

    Article  Google Scholar 

  • Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9.

    Article  Google Scholar 

  • Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–97.

    Article  Google Scholar 

  • Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789–98.

    Article  Google Scholar 

  • Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–27.

    Article  CAS  Google Scholar 

  • Boulet L-P, Chapman KR, Côté J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, DeVault A, Fick RB Jr, Cockcroft DW. Inhibitory effects of an anti-lgE antibody E25 on allergen – induced early asthmatic response. Am J Respir Crit Care Med. 1997;155:1835. https://doi.org/10.1164/ajrccm.155.6.9196083.

    Article  CAS  PubMed  Google Scholar 

  • Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125:1378–86.

    Article  CAS  Google Scholar 

  • Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the “real-world” effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107:1141–51.

    Article  Google Scholar 

  • Brightling CE, Chanez P, Leigh R, O’Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:692–701.

    Article  CAS  Google Scholar 

  • Brownell J, Casale TB. Anti-IgE therapy. Immunol Allergy Clin N Am. 2004;24:551–68.

    Article  Google Scholar 

  • Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–90.

    Article  CAS  Google Scholar 

  • Busse WW, Israel E, Nelson HS, Baker JW, Charous L, Young DY, Vexler V, Shames RS. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008;178:1002–8.

    Article  CAS  Google Scholar 

  • Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Sorkness C. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005–15.

    Article  CAS  Google Scholar 

  • Busse W, Spector S, Rosén K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132:485. https://doi.org/10.1016/j.jaci.2013.02.032.

    Article  PubMed  Google Scholar 

  • Cahill KN, Katz HR, Cui J, Lai J, Kazani S, Crosby-Thompson A, Garofalo D, Castro M, Jarjour N, DiMango E, Erzurum S, Trevor JL, Shenoy K, Chinchilli VM, Wechsler ME, Laidlaw TM, Boyce JA, Israel E. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med. 2017;376:1911–20.

    Article  CAS  Google Scholar 

  • Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, McAlary M, Fowler-Taylor A, Racine A, Gupta N, Fick R, Della Cioppa G. Effect of omalizumab on symptoms of seasonal allergic rhinitis. JAMA. 2001;286:2956–67.

    Article  CAS  Google Scholar 

  • Casale TB, Bernstein JA, Maurer M, Saini SS, Trzaskoma B, Chen H, Grattan CE, Gimenéz-Arnau A, Kaplan AP, Rosén K. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J Allergy Clin Immunol Pract. 2015;3:743–50.e1.

    Article  Google Scholar 

  • Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Jeffrey Wilkins H, Henkel T, Nair P. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125–32.

    Article  CAS  Google Scholar 

  • Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O’Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–66.

    Article  CAS  Google Scholar 

  • Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, Shen H, Fox H. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91:160–7.

    Article  CAS  Google Scholar 

  • Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400.

    Article  Google Scholar 

  • Cockle SM, Stynes G, Gunsoy NB, Parks D, Alfonso-Cristancho R, Wex J, Bradford ES, Albers FC, Willson J. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison. Respir Med. 2017;123:140–8.

    Article  Google Scholar 

  • Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003;111:87–90.

    Article  CAS  Google Scholar 

  • Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799–810.

    Article  Google Scholar 

  • Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377: 936–46.

    Article  CAS  Google Scholar 

  • Cox L, Platts-Mills TAE, Finegold I, Schwartz LB, Simons FER, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120:1373–7.

    Article  CAS  Google Scholar 

  • Fahy JV, Fleming HE, Wong HH, Llu JT, Su JQ, Reimann J, Fick RB, Boushey HA. The effect of an anti-lgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155:1828–34.

    Article  CAS  Google Scholar 

  • Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.

    PubMed  Google Scholar 

  • Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5:568–76.

    Article  CAS  Google Scholar 

  • FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388: 2128–41.

    Article  CAS  Google Scholar 

  • FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2017;2600:1–14.

    Google Scholar 

  • Gauvreau GM, Boulet LP, Leigh R, Cockcroft DW, Killian KJ, Davis BE, Deschesnes F, Watson RM, Swystun V, Kärrman Mardh C, Wessman P, Jorup C, Aurivillius M, O’Byrne PM. A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Respir Crit Care Med. 2015;191:161–7.

    Article  Google Scholar 

  • Genentech. FDA Approves Xolair, Biotechnology Breakthrough for Asthma. 2003. https://www.gene.com/media/press-releases/6287/2003-06-20/fda-approves-xolair-biotechnology-breakt.

  • Gergen PJ, Mitchell H, Lynn H. Understanding the seasonal pattern of childhood asthma: results from the National Cooperative Inner-City Asthma Study (NCICAS). J Pediatr. 2002;141:631–6.

    Article  Google Scholar 

  • Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128:989–95.

    Article  CAS  Google Scholar 

  • Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P, Bachert C. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110–6.e1.

    Article  CAS  Google Scholar 

  • Gonem S, Berair R, Singapuri A, Hartley R, Laurencin MFM, Bacher G, Holzhauer B, Bourne M, Mistry V, Pavord ID, Mansur AH, Wardlaw AJ, Siddiqui SH, Kay RA, Brightling CE. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016;4:699–707.

    Article  CAS  Google Scholar 

  • Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–84.

    Article  CAS  Google Scholar 

  • Haldar P, Brightling CE, Singapuri A, Hargadon B, Gupta S, Monteiro W, Bradding P, Green RH, Wardlaw AJ, Ortega H, Pavord ID. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014;133:921–3.

    Article  CAS  Google Scholar 

  • Hanania NA, Wenzel S, Roseń K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–11.

    Article  CAS  Google Scholar 

  • Hirai H, Tanaka K, Yoshie O. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193:255–61.

    Article  CAS  Google Scholar 

  • Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin. 2001;17:233–40.

    Article  CAS  Google Scholar 

  • Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh K-M, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy Eur J Allergy Clin Immunol. 2005;60:309–16.

    Article  CAS  Google Scholar 

  • Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017;139:1489–95.e5.

    Article  CAS  Google Scholar 

  • Johnston NW, Johnston SL, Duncan JM, Greene JM, Kebadze T, Keith PK, Roy M, Waserman S, Sears MR. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol. 2005;115:132–8.

    Article  Google Scholar 

  • Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122: 569–73.

    Article  CAS  Google Scholar 

  • Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, Stirling RG, Kuna P, Berger W, Maurer M, Rosén K. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101–9.

    Article  CAS  Google Scholar 

  • Knutsen R. Novartis aims to bring first oral asthma drug to market in two decades. In: MM&M. 2017. http://www.mmm-online.com/pipeline/novartis-nvs-first-to-market-oral-asthma-respiratory-drug-in-two-decades/article/645364/.

  • Kraft M, Martin R, Lazarus S. Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids. Chest. 2003;124:42.

    Article  Google Scholar 

  • Krug N, Hohlfeld JM, Kirsten A-M, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med. 2015;372:1987–95.

    Article  Google Scholar 

  • Krug N, Hohlfeld JM, Buhl R, Renz J, Garn H, Renz H. Blood eosinophils predict therapeutic effects of a GATA3-specific DNAzyme in asthma patients. J Allergy Clin Immunol. 2017;140:625–8.e5.

    Article  CAS  Google Scholar 

  • Kuna P, Aurivillius M, Jorup C, Prothon S. Efficacy and tolerability of an inhaled selective glucocorticoid receptor modulator – AZD5423 – in chronic obstructive pulmonary disease patients: phase II study results. Basic Clin Pharmacol Toxicol. 2017;121:279–89.

    Article  CAS  Google Scholar 

  • Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124:1210–6.

    Article  CAS  Google Scholar 

  • Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosén K, Chipps BE, Luskin AT, Solari PG. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140:162–9.e2.

    Article  CAS  Google Scholar 

  • Li J, Wang F, Lin C, Du J, Xiao B, Du C, Sun J. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: a systematic review and meta-analysis. J Asthma. 2017;54:300–7.

    Article  CAS  Google Scholar 

  • Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study. J Allergy Clin Immunol. 2016;138:913–5.e2.

    Article  CAS  Google Scholar 

  • Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, Iribarren C, Chen H, Carrigan G, Rosén K, Szefler SJ. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134:560. https://doi.org/10.1016/j.jaci.2014.02.007.

    Article  CAS  PubMed  Google Scholar 

  • Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38:2058–70.e1.

    Article  CAS  Google Scholar 

  • Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Ortega H. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy Eur J Allergy Clin Immunol. 2016;71:1335–44.

    Article  CAS  Google Scholar 

  • Maurer M, Rosén K, Hsieh H-J, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.

    Article  CAS  Google Scholar 

  • Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med. 1999;341:1966–73.

    Article  CAS  Google Scholar 

  • Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (Omalizumab). Pediatrics. 2001;108:e36.

    Article  CAS  Google Scholar 

  • Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127:1622–4.

    Article  Google Scholar 

  • Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O’Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–93.

    Article  CAS  Google Scholar 

  • Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–58.

    Article  CAS  Google Scholar 

  • Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol. 2003;131:46–52.

    Article  CAS  Google Scholar 

  • Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children (review). Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD003559.pub4. www.cochranelibrary.com.

  • Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald M, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–207.

    Article  Google Scholar 

  • Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549–56.

    Article  CAS  Google Scholar 

  • Otani IM, Anilkumar AA, Newbury RO, Bhagat M, Beppu LY, Dohil R, Broide DH, Aceves SS. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2013;131:1576–82.e2.

    Article  CAS  Google Scholar 

  • Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140:633–43.

    Article  Google Scholar 

  • Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–9.

    Article  CAS  Google Scholar 

  • Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol. 2007;21:428–32.

    Article  Google Scholar 

  • Pinto J, Mehta N, DiTineo M, Wang J, Baroody F, Naclerio R. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48:318–24.

    CAS  PubMed  Google Scholar 

  • Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, Molfino NA. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41: 330–8.

    Article  CAS  Google Scholar 

  • Polk BI, Rosenwasser LJ. Biological therapies of immunologic diseases: strategies for Immunologic Interventions. Immunol Allergy Clin North Am. 2017;37: 247–59.

    Article  Google Scholar 

  • Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28–35.

    Article  CAS  Google Scholar 

  • Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Baskan EB, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Rosén K. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on h 1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67–75.

    Article  Google Scholar 

  • Sanofi. Evaluation of dupilumab in patients with persistent asthma (Liberty Asthma Quest). In: ClinicalTrials.gov. 2017a. https://clinicaltrials.gov/ct2/show/NCT02414854.

  • Sanofi. Evaluation of dupilumab in patients with severe steroid dependent asthma (VENTURE). In: ClinicalTrials.gov. 2017b.

    Google Scholar 

  • Sanofi. Evaluation of dupilumab in children with uncontrolled asthma (VOYAGE). In: ClinicalTrials.gov. 2018a. https://clinicaltrials.gov/ct2/show/NCT02948959.

  • Sanofi. Evaluation of dupilumab’s effects on airway inflammation in patients with asthma (EXPEDITION). In: ClinicalTrials.gov. 2018b. https://clinicaltrials.gov/ct2/show/NCT02573233.

  • Sanofi. Long-term safety evaluation of dupilumab in patients with asthma (LIBERTY ASTHMA TRAVERSE). In: ClinicalTrialsgov. 2018c.

    Google Scholar 

  • Sheikh J. Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Clin Immunol. 2005;5:403–7.

    Article  CAS  Google Scholar 

  • Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics. 2004;113:e308–12.

    Article  Google Scholar 

  • Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour J-P, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NMH, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–48.

    Article  CAS  Google Scholar 

  • Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–61.

    Article  Google Scholar 

  • Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G III, O’Gorman MA, Abonia JP, Young J, Henkel T, Wilkins HJ, Liacouras CA. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129:456–63.e3.

    Article  CAS  Google Scholar 

  • Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, Filipovich AH, Assa’ad AH, Rothenberg ME. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2006;118:1312–9.

    Article  CAS  Google Scholar 

  • Steinke JW, Rosenwasser LJ, Borish L. Cytokines in allergic inflammation. In: Adkinson Jr NF, Bochner B, Burks AW, Busse W, Holgate S, Lemanske R, O’Hehir RE, editors. Middleton’s allergy principles and practice. 8th ed. Philadelphia: Elsevier; 2014. p. 65–83.

    Google Scholar 

  • Stokes JR, Casale TB. Characterization of asthma endotypes: implications for therapy. Ann Allergy Asthma Immunol. 2016;117:121–5.

    Article  CAS  Google Scholar 

  • Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann B, Beglinger C, Smith DA, Patel J, Byrne M, Simon H-U. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59:21–30.

    Article  CAS  Google Scholar 

  • Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ, Calatroni A, Wildfire JJ, Gergen PJ, Cohen RT, Pongracic JA, Kercsmar CM, Khurana Hershey GK, Gruchalla RS, Liu AH, Zoratti EM, Kattan M, Grindle KA, Gern JE, Busse WW, Szefler SJ. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136: 1476–85.

    Article  CAS  Google Scholar 

  • Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2:332–40.

    Article  Google Scholar 

  • Wenzel S. Dupilumab compassionate use study. In: ClinicalTrials.gov. 2017.

    Google Scholar 

  • Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Vancopoulos GD, Graham N, Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–66.

    Article  CAS  Google Scholar 

  • Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Rand Sutherland E, Evans RR, Joish VN, Eckert L, Graham NMH, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet (London, England). 2016;388:31–44.

    Article  CAS  Google Scholar 

  • Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, Plaut M, Sampson HA. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137:1103–10.e11.

    Article  CAS  Google Scholar 

  • Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Arron JR, Koth LL, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–95.

    Article  CAS  Google Scholar 

  • Xue L, Gyles S, Wettey F. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol. 2005;175:6531–6.

    Article  CAS  Google Scholar 

  • Xue L, Barrow A, Pettipher R. Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol. 2009;182:7580–6.

    Article  CAS  Google Scholar 

  • Yancey SW, Ortega HG, Keene ON, Mayer B, Gunsoy NB, Brightling CE, Bleecker ER, Haldar P, Pavord ID. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J Allergy Clin Immunol. 2017;139:1167–75.e2.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, MO, USA

    Christina G. Kwong & Jeffrey R. Stokes

Authors
  1. Christina G. Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey R. Stokes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey R. Stokes .

Editor information

Editors and Affiliations

  1. Milton S Hershey Med Ctr, Penn State University Milton S Hershey Med Ctr, Hershey, PA, USA

    Timothy Craig

  2. Suite 502, Allergy, Asthma and Immunology Suite 502, Tampa, FL, USA

    Dennis K. Ledford

Section Editor information

  1. Division of General Medicine/Department of Medicine, University of California, San Francisco, CA, USA

    Massoud Mahmoudi

  2. Department of Medicine and Pediatrics, Penn State College of Medicine, Hershey, PA, USA

    Timothy Craig

  3. Division of Allergy & Immunology, Dept. of Internal Medicine, University of South Florida Morsani College of Medicine, James A Haley Veterans' Hospital, Asthma and Immunology Associates of Tampa Bay, Tampa, Florida, USA

    Dennis K. Ledford

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Kwong, C.G., Stokes, J.R. (2018). Biologic and Emerging Therapies for Allergic Disease. In: Craig, T., Ledford, D. (eds) Allergy and Asthma. Springer, Cham. https://doi.org/10.1007/978-3-319-58726-4_43-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-58726-4_43-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-58726-4

  • Online ISBN: 978-3-319-58726-4

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation